The incidence of PD-L1 over-expression in NSCLC has been reported to vary from 19.6% to 65.9% and its association with clinicopathological features as well as patients' prognosis is very controversial [18–21]. The gene discussed is CD274; the disease is non-small cell lung carcinoma.